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Progression of tumors depends on interactions of cancer cells with the host environment. Expres-
sion of the cytoskeleton protein VASP is upregulated in various cancer entities. We analyzed the role
of VASP for melanoma growth in murine allograft models. Growth of VASP expressing melanomas
was retarded in VASP/ versus wild-type animals. Over time tumor size was <50% in VASP/ versus
wild-type animals and independent of expression levels of Ena/VASP protein family members. His-
tological analyses showed smaller cells with impaired nutrition status and less vascularization in
melanomas derived from VASP/ versus counterparts from wild-type mice. Cumulatively, the data
reveal a critical role of VASP in non-tumor cells in the tumor environment for melanoma growth
in vivo.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Regulation of the actin cytoskeleton plays a central role in cell
migration, proliferation, and progression. Directed endothelial
cytoskeleton turnover is the driving force for angiogenesis that
leads to vascular lumen formation. Steps of elongation and recruit-
ment of endothelial cells to the sites of neovascularization in solid
tumors require changes in cell polarity and migration, thus indicat-
ing a crucial role of actin-regulatory proteins in cancer growth.
The cytoskeleton protein vasodilator-stimulated phosphopro-
tein (VASP) is the founding member of the Enabled (Ena)/VASP
family and activity of the protein is regulated by complex phos-
phorylation patterns mediated by cyclic nucleotide- and AMP-
dependent protein kinases [1,2]. In mammalians, the Ena/VASPchemical Societies. Published by E
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Stockholm, Sweden. Fax: +46family comprises the mammalian Ena homolog (Mena), VASP,
and the Ena-VASP-like protein (EVL). The family members share
a tripartite domain organization of an N-terminal Ena/VASP
homology 1 (EVH1) domain, a central proline-rich region (PRR),
and a C-terminal Ena/VASP homology 2 (EVH2) domain [3]. The
EVH2 domain mediates VASP binding to globular actin (G-actin)
and ﬁlamentous actin (F-actin) [4]. VASP and its phosphorylated
forms couple cyclic nucleotide- and AMP-dependent signal trans-
duction pathways to the cytoskeleton and the cytoskeleton-mem-
brane interface [5]. VASP is ubiquitously found in adult and
embryonic tissues [5,6], and highly expressed in vascular endothe-
lial cells [7]. In endothelial cells, VASP is localized to actin ﬁlaments
and enriched in highly dynamic membrane regions and is a crucial
factor in the formation and bundling of actin ﬁlaments [3]. Over-
expression of VASP in the endothelium has been shown to induce
stress ﬁber formation [7], whereas loss of VASP function results in
loose cell-cell contacts [2]. Ablation of the VASP gene in mice re-
sults in minor if any phenotype [5], whereas combined deﬁciency
in all Ena/VASP proteins is embryo-lethal and mice die during
development from edema and bleedings due to defective vessel
integrity [8].
Several studies reported that VASP expression levels have been
associated with tumorigenesis in cell culture and mouse modelslsevier B.V. All rights reserved.
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nomaand increaseswithmore advanced tumor stages. Consistently,
elevated VASP expression levels increase invasive migration of hu-
man breast cancer cells [10]. As VASP expression is up-regulated
in solidmalignant cancers, we reasoned that targeting VASP activity
might interfere with tumor growth. Here, we challenged VASP/
and wild-type (WT) mice using the B16 allograft melanoma model.
We found that tumor growthwas largely impaired in VASP deﬁcient
animals.Melanomas inVASP/mice contain >3-timesmore vessels
as compared to cancers isolated fromWTanimals.We conclude that
VASP expression in the tumor environmenthas a critical function for
melanoma growth in vivo and that VASP is a potential drug target to
interfere with malignant diseases.
2. Materials and methods
2.1. Cell culture
B16 murine melanoma cells were cultivated in DMEM medium
supplemented with 10% fetal bovine serum, 100 IU/ml penicillin,
and 100 lg/ml streptomycin (Gibco, Breda, The Netherlands) at
37 C in a 5% CO2 atmosphere.
2.2. Mouse melanoma model
VASP/ mice used in the study were described previously [5].
Control female WT C57Bl/6 mice, 6–8 weeks of age, were pur-
chased from Charles River Wiga (Sulzfeld, Germany). All proce-
dures were approved by local authorities. For tumor induction,
2.5  106 B16.F10 melanoma cells were subcutaneously inoculated
into the right dorsal ﬂank of VASP/ and WT mice. All mice in the
study were challenged by a single melanoma only. Animals were
divided into four groups, which were analyzed at day 8 (7 WT, 2
VASP/ mice), day 10 (7 WT, 6 VASP/), day 12 (5 WT, 3
VASP/), and day 14 (7 WT, 5 VASP/) after injection. Animals
were sacriﬁced, dark tumor masses were carefully and completely
removed en bloc from the surrounding tissue, and weights and
sizes of the excised melanoma were determined. Part of the tumor
tissue was ﬁxed in phosphate buffered 4% formaldehyde for histo-
logical analysis.
2.3. Immunohistological studies
Histological analysis and staining of melanoma in WT and
VASP/ mice were performed as described [13]. Images were ta-
ken using a Nikon Coolpix 5000 camera mounted on an Olympus
BX51 microscope with a PlanApo 40 objective. To determine
the mitotic count ten high power ﬁelds (HPF, 400 magniﬁcation)
of each tumor were evaluated. Tumor vascularization was quanti-
ﬁed in analogy to the mitotic count and blood vessels in ten repre-
sentative HPF were counted.Fig. 1. Melanoma size in WT and VASP/mice. Melanoma were resected en bloc fromW
corresponds to 1 cm.2.4. Statistical analysis
Results are expressed as mean ± standard deviation (S.D.). Dif-
ferences between groups were determined by Student’s t-test.
Means and S.D. of melanoma weights were calculated from tumors
of 7 WT and 2 VASP/ mice at day 8; 7 WT and 6 VASP/ at day
10; 5 WT and 3 VASP/ at day 12 and 7 WT, 5 VASP/ at day 14.
Values of P < 0.05 were considered statistically signiﬁcant.
3. Results
3.1. VASP deﬁciency interferes with melanoma growth
To analyze VASP function for melanoma growth, we used the
B16 melanoma model in mice. To trigger allograft melanoma for-
mation, B16 cells were subcutaneously injected into the right dor-
sal ﬂank of 6–8 weeks old VASP/ andWTmice, respectively. Solid
tumors became palpable around day 6 after cell injection. At day 8,
10, 12, and 14 after B16 cell injection, mice were sacriﬁced and tu-
mors were carefully resected en bloc from the surrounding tissues,
and size and masses of the excised melanoma were determined. At
all time-points size (Fig. 1) and weight (Fig. 2) of melanomas were
largely reduced in VASP/mice as compared to WT animals
(0.011 ± 0.013 vs. 0.046 ± 0.021 g at day 8 after injection;
0.115 ± 0.056 vs. 0.370 ± 0.111 g at day 10; 0.469 ± 0.290 vs.
0.699 ± 0.138 g at day 12 and 0.864 ± 0.526 vs. 1.666 ± 0.222 g at
day 14). Tumor weight in VASP/ mice was reduced by 23.9%,
31.1%, 67.1%, and 51.9% at day 8, 10, 12, and 14, respectively, as
compared to WT mice (Fig. 2).
3.2. Constant Ena/VASP protein expression in growing melanoma
We analyzed endogenous VASP expression in resected mela-
noma tissue (Fig. 3).
Western blotting using VASP speciﬁc antibody M4 showed con-
stant VASP levels in tissue lysates over time. VASP content was
similar in tumors growing in VASP/ and WT mice. Expression
of Mena and EVL in the melanoma tissue as assessed by Western
blotting or RT-PCR did not change either over time and was indis-
tinguishable in VASP/ and WT mice (not depicted). The data sug-
gest that growth reduction in melanomas in VASP/ animals is
due to deﬁciency of exogenous VASP in the tumor environment
of the host tissue rather than caused by alterations of endogenous
protein in the malignant cells.
3.3. Reduced nutritional status caused by defective angiogenesis in
melanoma growing in VASP null mice
To analyze consequences of VASP deﬁciency in the melanoma-
surrounding tissue for tumor growth, we performed histological
analysis of formalin ﬁxed and parafﬁn embedded cross-sectionsT and VASP/ (KO) mice at day 8, 10, 12, and 14 after injection, respectively. The bar
Fig. 2. Comparison of melanoma weights. Melanoma from WT (dark columns) and
VASP/ (light columns) mice were carefully resected in total at day 8 (7 WT, 2
VASP/mice), 10 (7 WT, 6 VASP/), 12 (5 WT, 3 VASP/), and 14 (7 WT, 5 VASP/
) after B16 cell injection and weighed. Means ± S.D. are shown, P < 0.05. An asterisk
indicates a statistically signiﬁcant difference between the two groups.
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ylin-Eosin (Fig. 4). Melanoma cells growing in VASP/ mice
showed considerably smaller cell sizes and volume associated with
a lower cytoplasm/nucleus-ratio versus tumor cells fromWT mice.
Tumor cells growing in VASP/ mice showed strong cytoplasmic
eosinophilia pointing to reduced tissue oxygen content. Average
mitotic count in tumors from WT mice signiﬁcantly exceeded lev-Fig. 4. Histology of melanoma derived from (A) WT and (B) VASP/mice. Hematoxylin-
arrows indicate mitoses. The asterisk marks apoptotic cells. A representative image of 5
Fig. 3. 3 VASP expression in B16 melanoma derived from WT and VASP/ mice. Homog
respectively, were separated in 10% SDS–PAGE under reducing conditions. 10 lg of pro
VASP using anti-VASP antibody M4.els in melanoma from VASP/mice (0.7 ± 0.5 vs. 2.3 ± 0.7mitoses/
HPF). Consistently, vascularization was largely reduced in mela-
noma in VASP/ mice (5.4 ± 1.6 vessels/HPF) as compared to tu-
mors isolated from WT mice (14.8 ± 2.9 vessels/HPF). Taken
together, histological analysis is consistent with impaired mela-
noma growth in VASP/ mice and suggests that VASP deﬁciency
interferes with cancer cell nutritional status involving angiogenesis
defects.
4. Discussion
Growth of malignant tumors is a highly complex process and
critically depends on establishing blood supply. Using allograft
melanoma tumor models in genetically altered mice, we showed
that deﬁciency in the actin-binding protein VASP in the tumor
environment, but not in the malignant cells, interferes with mela-
noma growth involving defects in neovascularization.
VASP has been originally identiﬁed in human platelets, however
the protein is highly expressed in vascular endothelial and smooth
muscle cells. Its expression is elevated during the endothelial reor-
ganization phase of capillary morphogenesis in vitro [1,7], and in
highly vascularized tissues such as the lung and kidney [6]. More-
over, VASP expression is up-regulated during vasculogenesis and
angiogenesis in placental development [14]. VASP contributes to
stabilization of endothelial cell-cell contacts and improves vascular
barrier functions via Rho GTPase Rac 1 [15] and aII-spectrin-depen-
dent mechanisms [2].
Vice versa deﬁciency in VASP impairs formation of cortical actin
cytoskeleton and increases basal and stimulated vascular perme-Eosin stained cross-sections of melanoma at day 14 fromWT and VASP/mice. The
mice per genotype is shown, original magniﬁcation 400.
enates of B16 melanoma tissue from WT and VASP/ mice at day 8, 10, 12 and 14,
tein was loaded per lane. Following electrotransfer Western blots were probed for
2536 Y.M. Kim et al. / FEBS Letters 585 (2011) 2533–2536ability [2]. Consistent with mutual compensation of individual
members of the Ena/VASP family, the leakage phenotype exacer-
bates in mice with triple deﬁciency in all family members and mice
die during development due to edema and abnormal vessel devel-
opment [8]. Sealing of newly formed vessels is a key mechanism in
angiogenesis. Reduced VASP activity interferes with formation and
stabilization of new vessels [16], which often display abnormal in-
creased vascular permeability. Dependent on conﬂuence state and
cell-cell contact formation endothelial cells switch between highly
motile, ﬁbroblastoid and epitheloid, ‘‘resting’’ phenotypes. In chal-
lenged conditions, e.g. in scratch models, the phenotype switches
and cell motility of VASP deﬁcient cells is impaired [17], and thus
negatively modulates neovascularization. Therefore, the absence of
VASP in the tumor-surrounding environment but not in the tumor
itself interferes with cancer growth.
Vice versa, Ena/VASP proteins are upregulated in malignant dis-
eases and promote tumor cell migration. Over-expression of Mena
promotes the initial steps of tumor invasion in colorectal carcino-
mas, resulting in excessive invasiveness [11]. VASP expression is
up-regulated in human lung adenocarcinoma and increases with
more advanced tumor stages. Similarly, increased EVL expression
is found in human breast cancer. Increase in EVL mRNA levels
was found in 23 of the 35 (65.7%) tumor tissues and patients in
the advanced stages more frequently exhibited an elevated EVL
expression [12]. EVL expression was positively associated with
the clinical stages of human breast cancer, and it may be impli-
cated in invasion and/or metastasis of human breast cancer. Inhibi-
tion of VASP by siRNA showed that the higher expression levels of
VASP contribute to higher invasive migration capacity of the hu-
man breast cancer cell line MDA-MB-231 [10]. Besides modulation
of Ena/VASP expression levels, an invasion-speciﬁc isoform of
Mena (MenaINV) has been demonstrated to regulate carcinoma cell
invasion in response to epidermal growth factor (EGF) signaling,
involving lamellipodial protrusion and actin incorporation at
barbed ends. Response to EGF is critical for breast cancer invasion
and metastasis [18].
Complementary to VASP expression-driven actin ﬁber assem-
bly, phosphorylation patterns regulate the activity of the protein
[1,2]. VASP phosphorylation correlates with the reversible inhibi-
tion of integrin a2b3 that participates in angiogenesis in a vascular
endothelial growth factor (VEGF)-dependent manner [16]. Nitric
oxide (NO) is a downstream effector in VEGF-mediated angiogene-
sis and VASP phosphorylation at residue Ser239 by NO-stimulated
cGMP-dependent protein kinase results in loss of lamellipodial
protrusions [19].
In summary, our study identiﬁes a novel and unexpected role of
VASP in non-tumor cells for melanoma growth in vivo and suggests
that targeting VASP activity is a promising strategy to treat malig-
nant disease.
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